Supplier
NPI deactivated
Alivia Specialty, LLC
Alivia Specialty, LLC was paid $188.98M by Medicaid between Oct 2019 and Dec 2024, across 60 billing codes. Its largest line is J9271, Injection, pembrolizumab, 1 mg — 31% of everything it billed.
33Billing provider infoALIVIA SPECIALTY, LLC
GUAYNABO, PR 00934
GUAYNABO, PR 00934
33aNPI1306182548assigned 12/17/2012
33bProvider typeSpecialty Pharmacy
28Total paid$188.98M
24GClaims105,104
24DCodes billed60
24AFirst – last monthOct 2019 – Dec 2024
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2019 | 429 | $204K | |
| 2020 | 3,409 | $3.30M | |
| 2021 | 94 | $202.98 | |
| 2022 | 14,811 | $30.77M | |
| 2023 | 41,229 | $73.13M | |
| 2024incomplete | 45,132 | $81.58M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | 31% | 5,533 | 4,121 | $58.87M |
| J9035 | Injection, bevacizumab, 10 mg | 10% | 4,120 | 2,214 | $18.95M |
| J9299 | Injection, nivolumab, 1 mg | 7.7% | 1,620 | 1,055 | $14.58M |
| J9306 | Injection, pertuzumab, 1 mg | 7.5% | 2,374 | 1,678 | $14.10M |
| J9355 | Injection, trastuzumab, excludes biosimilar, 10 mg | 5.0% | 2,003 | 1,393 | $9.40M |
| J0897 | Injection, denosumab, 1 mg | 4.4% | 3,102 | 2,545 | $8.30M |
| J9358 | Injection, fam-trastuzumab deruxtecan-nxki, 1 mg | 3.9% | 715 | 465 | $7.29M |
| J9312 | Injection, rituximab, 10 mg | 3.3% | 1,159 | 653 | $6.22M |
| J2777 | Injection, faricimab-svoa, 0.1 mg | 3.0% | 2,380 | 1,704 | $5.68M |
| J9022 | Injection, atezolizumab, 10 mg | 2.8% | 540 | 401 | $5.35M |
| Q5107 | Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg | 2.4% | 1,565 | 768 | $4.62M |
| J9042 | Injection, brentuximab vedotin, 1 mg | 2.1% | 107 | 88 | $4.04M |
48 more codes
| J9145 | Injection, daratumumab, 10 mg | 2.0% | 528 | $3.85M |
| Q5117 | Injection, trastuzumab-anns, biosimilar, (kanjinti), 10 mg | 1.9% | 1,477 | $3.59M |
| J9055 | Injection, cetuximab, 10 mg | 1.9% | 446 | $3.50M |
| J9354 | Injection, ado-trastuzumab emtansine, 1 mg | 1.8% | 520 | $3.49M |
| J2353 | Injection, octreotide, depot form for intramuscular injection, 1 mg | 1.3% | 473 | $2.43M |
| J1569 | Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | 1.3% | 780 | $2.41M |
| J9264 | Injection, paclitaxel protein-bound particles, 1 mg | <1% | 221 | $1.51M |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 1,437 | $1.30M |
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase-fihj | <1% | 94 | $1.26M |
| J9317 | Injection, sacituzumab govitecan-hziy, 2.5 mg | <1% | 76 | $1.04M |
| J3380 | Injection, vedolizumab, intravenous, 1 mg | <1% | 146 | $966K |
| J9047 | Injection, carfilzomib, 1 mg | <1% | 97 | $795K |
| J0490 | Injection, belimumab, 10 mg | <1% | 238 | $794K |
| J9070 | Cyclophosphamide, 100 mg | <1% | 1,711 | $517K |
| J9395 | Injection, fulvestrant, 25 mg | <1% | 1,019 | $442K |
| J9202 | Goserelin acetate implant, per 3.6 mg | <1% | 599 | $428K |
| J2916 | Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg | <1% | 2,459 | $360K |
| J0640 | Injection, leucovorin calcium, per 50 mg | <1% | 4,774 | $318K |
| J7312 | Injection, dexamethasone, intravitreal implant, 0.1 mg | <1% | 177 | $300K |
| J9171 | Injection, docetaxel, 1 mg | <1% | 2,294 | $269K |
| J9305 | Injection, pemetrexed, not otherwise specified, 10 mg | <1% | 140 | $250K |
| J9075 | Injection, cyclophosphamide, not otherwise specified, 5 mg | <1% | 666 | $192K |
| J9263 | Injection, oxaliplatin, 0.5 mg | <1% | 3,123 | $182K |
| Q5115 | Injection, rituximab-abbs, biosimilar, (truxima), 10 mg | <1% | 75 | $151K |
| J3489 | Injection, zoledronic acid, 1 mg | <1% | 2,312 | $136K |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 1,238 | $130K |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | <1% | 67 | $121K |
| Q5119 | Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | <1% | 54 | $119K |
| J9267 | Injection, paclitaxel, 1 mg | <1% | 3,074 | $115K |
| J9190 | Injection, fluorouracil, 500 mg | <1% | 4,139 | $102K |
| J9206 | Injection, irinotecan, 20 mg | <1% | 1,912 | $92K |
| J9049 | Injection, bortezomib (hospira), not therapeutically equivalent to j9041, 0.1 mg | <1% | 474 | $90K |
| J9045 | Injection, carboplatin, 50 mg | <1% | 3,162 | $84K |
| J9000 | Injection, doxorubicin hydrochloride, 10 mg | <1% | 2,188 | $51K |
| J9201 | Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | <1% | 712 | $44K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 13,662 | $40K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 8,716 | $31K |
| J9060 | Injection, cisplatin, powder or solution, 10 mg | <1% | 632 | $27K |
| J9044 | Injection, bortezomib, not otherwise specified, 0.1 mg | <1% | 13 | $25K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 10,216 | $21K |
| J9181 | Injection, etoposide, 10 mg | <1% | 66 | $3K |
| J9370 | Vincristine sulfate, 1 mg | <1% | 187 | $3K |
| J1750 | Injection, iron dextran, 50 mg | <1% | 13 | $2K |
| S0028 | Injection, famotidine, 20 mg | <1% | 1,917 | $2K |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 207 | $2K |
| J9130 | Dacarbazine, 100 mg | <1% | 24 | $725.39 |
| J3490 | Unclassified drugs | <1% | 1,149 | $625.50 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 182 | $490.76 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSABNANI, HARI (PRESIDENT & CEO)
| Provider | Location | Paid |
|---|---|---|
| Alivia Infusion Services LLC | Ponce, PR | $10.93M |
| Plaza Health LLC | Bayamon, PR | $3K |
| Plaza Health LLC | Toa Baja, PR | $2K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.